Table 1.
Baseline characteristics of included patients. ALBI: Albumin-Bilirubin Grade. BCLC: Barcelona clinic liver cancer. ECOG: Eastern Cooperative Oncology Group Performance Score. HBV: hepatitis B virus. HCV: hepatitis C virus. RFA: radiofrequency ablation. TARE: transarterial radioembolization.
| Pt# Age/Sex |
Cause | BCLC Stage |
ECOG | Child Pugh |
ALBI | Tumor Number |
Largest Tumor | Prior Treatment | Treatment Rationale | Time of TARE from diagnosis (month) | Treatment Sequence |
|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 36F |
Idiopathic | B | 1 | Non-cirrhotic | 1 | >3 | 5.4 | Surgery | Multifocal lesion with new lesions on Atezo/Bev | 8 9 17 |
Two sequential sessions. One concurrent session. |
| #2 66 M |
NASH | B | 0 | B | 2 | >1 | 3.2 | TARE | Palliative versus transplant. | 13 | Sequential. TARE 1 mo prior to Atezo/Bev started. |
| #3 64 M |
HCV | B | 0 | A | 1 | >3 | 9.9 | None | Multifocal with dominant lesions | 2 6 11 |
Sequential and concurrent: 1st TARE session 1 month to Atezo/Bev initiation. 2nd and 3rd TARE 3 mo and 8mo after Atezo/Bev started. |
| #4 63 M |
HCV | B | 0 | Non-cirrhotic | 2 | 2 | 15.1 | None | Multifocal with dominant lesions | 2 3 |
Sequential. Atezo/Bev started 3 mo and 2 mo after the first and second TARE. |
| #5 68 M |
HCV | C | 2–3 | B | 3 | >3 | 5.8 | None | Multifocal lesion with slightly increased dominant lesion on Atezo/Bev | 9 | Atezo/Bev started 8 months prior to TARE. |
| #6 66 M |
HBV | C | 0 | A | 1 | >3 | 6.7 | None | Multifocal with dominant lesions | 3 | Sequential. Atezo/Bev started less than 1 month after TARE. |
| #7 78 M |
HCV EtOH |
C | 1 | A | 1 | 1 | 9.8 | None | Dominant lesion with omental nodularity | 4 | Sequential. Atezo/Bev started 2 mo after TARE. |
| #8 63 M |
HCV EtOH |
C | 2–3 | A | 1 | >3 | Confluent | None | Confluent. Palliative. | 3 | Concurrent. 1 cycle Atezo/Bev was administered. 1 month prior to TARE. |
| #9 57 M |
HCV EtOH |
C | 1 | A | 2 | 2 | 7.5 | RFA | Multifocal lesion with persistent disease on Atezo/Bev | 10 | Sequential; 6 months of Atezo/Bev treatment ending 1 month prior to TARE. |
| #10 72 M |
HCV | C | 1 | A | 2 | >3 | 1.0 | TARE, sorafenib | Multifocal lesion with progressed disease on Atezo/Bev | 25 | Sequential. 14 month Atezo/Bev ending 1 month prior to TARE. |